By a GenomeWeb staff reporter

NEW YORK (GenomeWeb News) – Agendia, AstraZeneca, and the Netherlands Cancer Institute today announced a collaboration to identify specific molecular subtypes of colorectal cancer in order to develop targeted therapies.

As part of the deal, Agendia will provide molecular data, bioinformatics support, and diagnostics expertise to AstraZeneca to define subpopulations within colorectal cancer, which kills about 500,000 people in the US and Europe each year, the partners said.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.